Search

Cluster studies identified a subgroup of patients with psychosis whose premorbid adjustment deteriorates before the onset, which may reflect variation in genetic influence. However, other studies reported a complex relationship between distinctive patterns of cannabis use and cognitive and premorbid impairment that is worthy of consideration. We examined whether: (1) premorbid social functioning (PSF) and premorbid academic functioning (PAF) in childhood and adolescence and current intellectual quotient (IQ) define different clusters in 802 first-episode of psychosis (FEP) patients; resulting clusters vary in (2) polygenic risk scores (PRSs) for schizophrenia (SCZ_PRS), bipolar disorder (BD_PRS), major depression (MD_PRS), and IQ (IQ_PRS), and (3) patterns of cannabis use, compared to 1,263 population-based controls. Four transdiagnostic clusters emerged (BIC = 2268.5): (1) high-cognitive-functioning (n = 205), with the highest IQ (Mean = 106.1, 95% CI: 104.3, 107.9) and PAF, but low PSF. (2) Low-cognitive-functioning (n = 223), with the lowest IQ (Mean = 73.9, 95% CI: 72.2, 75.7) and PAF, but normal PSF. (3) Intermediate (n = 224) (Mean_IQ = 80.8, 95% CI: 79.1, 82.5) with low-improving PAF and PSF. 4) Deteriorating (n = 150) (Mean_IQ = 80.6, 95% CI: 78.5, 82.7), with normal-deteriorating PAF and PSF. The PRSs explained 7.9% of between-group membership. FEP had higher SCZ_PRS than controls [F(4,1319) = 20.4, P

Objective: Stereotyped beliefs about schizophrenia are well-established in the society and relatively common among healthcare professionals and students. The aim of this study was to investigate the opinions about the causes, treatment, and outcome of schizophrenia among healthcare students. Method: Undergraduate nursing and psychology students completed selected items of the Opinion on Mental Illness Questionnaire after reading a clinical vignette of undiagnosed schizophrenia. Results: Students who labelled the description as schizophrenia were more pessimistic regarding full recovery from the disorder. Those who acknowledged greater relevance to biogenetic risk factors were more convinced of the efficacy of medications. Respondents’ opinions on the efficacy of psychological interventions were more positive among psychology students than among nursing students. Conclusions: The study confirmed the associations of schizophrenia labelling with prognostic pessimism and beliefs about the efficacy of pharmacological treatment among future healthcare professionals. Students’ opinions were less influenced by differences between academic degree programs. Information about current recovery rate and comprehensive care for schizophrenia may support future healthcare professionals in the relationship and the clinical management of PWS.

Objectives This study aimed at investigating the relationship between perceived public stigma towards people with schizophrenia (PWS) and their family members in a large sample of medical and psychology students. We hypothesised that: a) schizophrenia labelling would be related to greater perceived public stigma; b) contact with PWS would be related with lower perceived stigma; c) perceived public stigma would be similar between medical and psychology students and would be higher among students attending the clinical stage compared to their pre-clinical colleagues. Methods Participants were 592 students attending either the pre-clinical or clinical stage of coursework in Medicine and Psychology, at the University of Palermo (Italy) (Tab. I). Study measures included a short socio-demographic questionnaire, the Devaluation of Consumers Scale (DCS), and the Devaluation Consumers Families Scale (DCFS). Results Students who identified schizophrenia in an unlabelled clinical description expressed greater perceived public stigma towards PWS (t = -2.895, p = 0.004) and their family members (t = -2.389, p = 0.017). A trend-level association was found between previous contact with PWS and lower perceived public stigma (t = 1.903, p = 0.058), which became significant for those students who had a more extensive contact (Mann-Whitney z = 2.063, p = 0.039). Compared to medical students, psychology students perceived greater public stigma towards PWS. No difference was observed between students at different stages of their academic coursework (Tab. II). In a multivariate linear regression model, schizophrenia labelling and degree course predicted perceived public stigma towards severe mental disorders. Conclusions This study replicated previous findings on the relationship between public stigma towards PWS, schizophrenia labelling, and contact with PWS. Perception of public stigma was similar among pre-clinical and clinical students and greater among psychology students. The findings suggest the importance of promoting a critical awareness of negative stereotypes towards schizophrenia among healthcare students, since the beginning of their coursework. In addition to correct information about schizophrenia, anti-stigma intervention should include contact with PWS who live in the community.

Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6 countries, we examined the extent to which IQ and both early academic (Academic Factor [AF]) and social adjustment (Social Factor [SF]) are related to the lifetime frequency of cannabis use in both patients and controls. We expected a higher IQ and a better premorbid social adjustment in psychotic patients who had ever used cannabis compared to patients without any history of use. We did not expect such differences in controls. In both patients and controls, IQ was 3 points higher among occasional-users than in never-users (mean difference [Mdiff] = 2.9, 95% CI = [1.2, 4.7]). Both cases and control daily-users had lower AF compared to occasional (Mdiff = -0.3, 95% CI = [-0.5; -0.2]) and never-users (Mdiff = -0.4, 95% CI = [-0.6; -0.2]). Finally, patient occasional (Mdiff = 0.3, 95% CI = [0.1; 0.5]) and daily-users (Mdiff = 0.4, 95% CI = [0.2; 0.6]) had better SF than their never-using counterparts. This difference was not present in controls (Fgroup*frequency(2, 2205) = 4.995, P = .007). Our findings suggest that the better premorbid social functioning of FEP with a history of cannabis use may have contributed to their likelihood to begin using cannabis, exposing them to its reported risk-increasing effects for Psychotic Disorders. © The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com.

si descrivono i dati relativi ad un campioni di pazienti affetti da disturbo psicotico all'esordio, come parte del progetto SGAP (Sicilian Genetic and Psychosis. tra i fattori di rischio implicati nell'insorgenza del disturbo si prende in esame il ruolo del consumo di cannabis mettendo a confronto i pazienti con un gruppo di cntrollo costituito da soggetti non psicotici. Emerge come l'età media di insorgenza del disturbo psicotico è stata più precoce per coloro che avevano fumato cannabis nel corso della vita (24.2 anni vs. 31.6 anni) mentre non è stata riscontrata nessuna differenza in relazione all'uso recente di cannabis.

Objectives This study aimed to assess the psychometric properties of the Italian versions of the Devaluation of Consumers Scale (DCS) and the Devaluation of Consumer Families Scale (DCFS), twoshort-scales examining public stigma towards people with mental disorders and their relatives. Methods The scales were administered to 117 individuals with a clinical diagnosis of affective or non-affective psychoses (ICD 10 criteria F20-29, F30-33). Translation procedures were carried out according to accepted standards. Internal reliability was assessed using Cronbach’s alpha coefficient. Convergent validity was evaluated in terms of correlation with the Global Functioning Scale (GAF) and with the Questionnaire on Users’ Opinions (QUO). Known-group validity was assessed comparing patients at first-episode of psychosis and patients with a history of psychosis of at least 3 years (long-term psychosis).Results The overall Cronbach’s alpha value was 0.85 for DCS and 0.81for DCFS; subscales’ alpha values ranged from 0.80 to 0.55 for DCS, and from 0.68 to 0.55 for DCFS. Negative correlations were found between the Italian DCS and the DCFS total score and the QUO affective problems (DCS -0.33; DCFS -0.235) and social distance subscales (DCS -0.290; DCFS -0.356). Moreover, the GAF positively correlated with some of the DCS and DCFS subscales. Patients with long-term psychosis had higher scores in most DCS and DCFS subscales. Conclusion The Italian translation of DCF and DCFS showed good internal consistency, known-group validity, and convergent validity. These psychometric properties support their application in routine clinical practice in Italy as well as their use in international studies.

Objective: This study aimed at describing the coping strategies used by patients of small burns (

Summary Objectives: Cannabis is the most widely used illicit drug globally and its use has been linked to an increased risk for psychotic disorders. An association between cannabis consumption and psychotic symptoms was consistently reported by several studies. This case-control study aimed to widen the current findings about the impact of cannabis exposure on the risk of psychosis, by investigating the pattern of cannabis consumption in a sample of first-episode of psychosis (FEP) patients compared to healthy controls. Material and methods: 68 individuals who presented for the first time to mental health services of Palermo (Italy) with an ICD-10 diagnosis of psychotic disorders and 74 healthy were enrolled as part of the Sicilian Genetics and Psychosis study. Psychopathological assessment and diagnosis were carried out by the Schedule for Clinical Assessment in Neuropsychiatry (SCAN). Socio-demographic data were collected by the modified version of the Medical Research Council (MRC) socio-demographic scale. All participants were interviewed using the Cannabis Experience Questionnaire – Modified Version to obtain a detailed assessment of lifetime patterns of cannabis and other illicit drug consumption. Logistic regression was applied to investigate the relationships between various aspects of cannabis use (lifetime use, age at first use, duration, and frequency of use) and case-control status while controlling for potential confounders. Results: Patients started cannabis consumption about 3 years earlier than the control group (t = 3.1, p = 0.002) and were 8 times more likely to having started using cannabis before 15 years (adjusted OR = 8.0, 95% CI 2.4-27) than controls. Furthermore cases were more likely to smoke more frequently than controls (adjusted OR = 4.4, 95% CI 1.08-18). We did not find a difference in duration of cannabis use between cases and controls. Conclusions: The findings suggest that cannabis exposure, and especially daily cannabis consumption, is associated with the risk for psychosis; however, the retrospective study design does not allow drawing firm conclusions about causality.

Differenti studi hanno riscontrato nei pazienti con diagnosi di disturbo psicotico una diffusa compromissione delle funzioni esecutive, in particolare della Working Memory, e una tendenza a prendere decisioni rapidamente dovuta ad errori nel processamento di raccolta delle informazioni presenti nel contesto (Jumping To Conclusion, JTC). Obiettivo del presente studio é quello indagare la presenza di una possibile correlazione tra Working Memory e Jumping To Conclusions in un campione di pazienti al primo episodio psicotico. Per il presente studio sono stati valutati 41 pazienti all’esordio psicotico (58,5% M), di età media 29,63 (DS=10,285) e 89 controlli sani (47,2% M), di età media 33,31 (DS=12,817). I dati hanno mostrato che il Jumping To Conclusions è presente in 45 degli 89 soggetti del gruppo di controllo (51,1%) e in 31 dei 38 individui del gruppo dei casi (81,6%). Dalle percentuali ricavate, si nota come il gruppo dei casi fosse più propenso a “saltare alle conclusioni” rispetto ai controlli (χ2=10,28; p=0,001). Per quanto riguarda i compiti di Working Memory, i pazienti psicotici hanno ottenuto punteggi peggiori rispetto ai controlli. Infine, le analisi di correlazione svolte all’interno del gruppo dei casi rilevano la presenza di una correlazione significativamente positiva tra il punteggio ottenuto al Beads Task e tutti i compiti di Working Memory: Digit Span (rho=0,28; p=0,003), Digit Symbol (rho=0,27; p=0,002), Arithmetic (rho=0,26; p=0,003) e Block Design (rho=0,29; p=0,001). I risultati esposti sembrano inoltre supportare, in accordo con la letteratura, l’ipotesi di una possibile correlazione tra alterazioni a carico della Working Memory e deficit di raccolta dati Jumping To Conclusions.

Objective: Only few studies have investigated social and personality characteristics of members of Italian organized criminal groups: Mafia, Camorra, ‘Ndrangheta, and Sacra Corona Unita. This study aimed to explore the most relevant social and clinical features of Mafia criminals and their psychopathic traits. Method: The Psychopathy Check List-Revised (PCL-R) and a socio-demographic questionnaire were administered to 30 condemned for Mafia crimes and imprisoned in the “Pagliarelli” district prison of Palermo (Italy). The results were investigated applying the methods of Network Theory. Results: The study identified two communities, which were statistically different in terms of history of juvenile delinquency, levels of education, and antisocial and deviant behaviours score at PCL-R. Conclusions: The onset of antisocial behaviour and educational achievement might be relevant variables in understanding mafia offences, as well as antisocial behaviours in general. Moreover, methodologies of Network Theory may be used to characterize real-world complex systems of sociological and clinical dates.

Aim: There are consistent evidence suggesting that psychotic disorders are associated to social disadvantage and isolation in adulthood, and research suggested that they these are not simply a consequence of the functional impairment related to onset of the disease (Stilo et al., 2013; Morgan et al., 2008). To date only a few studies have investigated the impact of social risk factors on psychosis in Italy. This study aimed to replicate existing findings in a case-control sample from Southern Italy. Methods: 134 individuals presenting for the first time to mental health services of Palermo (Italy) with an ICD 10 diagnosis of psychosis and 175 population controls from Palermo (Italy) were enrolled, as part of the Sicilian Genetics and Psychosis study. Information about current social indicators were collected by the modified version of the Medical Research Council (MRC) socio-demographic scale. Results: Cases and controls were different in terms of gender, age, family history for psychotic disorders, and education achievement. Unemployment, no relationship, and lack of close confidants were independently associated with psychotic disorders, and these associations were still significant after adjusting for confounders. However, in contrast with previous studies from Northern Europe, cases were more likely to live with their parents or other relatives, rather than alone. A cumulative index of social disadvantage was computed using unemployment, no relationship, and lack of close confidants (range 0-3). Controlling for gender, age, education level and family history of psychosis, there was evidence of an effect of increased risk for psychosis for individuals exposed to ≥ 2markers of social disadvantage. Conclusion: Unemployment, being single, and lack of close friends were significantly related with psychosis, while living alone was not. Moreover, in contrast with previous studies that found evidence of dose-response effect, in this sample individuals exposed to more than 2 markers of social disadvantage showed a five-fold increase in the odds for psychosis, suggesting the possibility of a threshold effect.

Background: Cannabis is one of the most commonly used drugs among young people across Europe (EMCDDA data 2014), Moreover, it is one of the most abused illicit drugs among patients suffering from schizophrenia (Linszen et al., 1994) and, particularly, in patients at their first episode of psychosis (Donoghue et al., 2011). Furthermore, patients suffering from psychosis with a history of cannabis use have an earlier age of onset of psychosis (AOP) than those who never used it (Di Forti et al., 2013). We aim to investigate if the reported association between use of cannabis and AOP is consistent across to European samples with expected differences in pattern of cannabis use (i.e. age at first use, frequency of use) Methods: Cannabis is one of the most commonly used drugs among young people across Europe (EMCDDA data 2014), Moreover, it is one of the most abused illicit drugs among patients suffering from schizophrenia (Linszen et al., 1994) and, particularly, in patients at their first episode of psychosis (Donoghue et al., 2011). Furthermore, patients suffering from psychosis with a history of cannabis use have an earlier age of onset of psychosis (AOP) than those who never used it (Di Forti et al., 2013). We aim to investigate if the reported association between use of cannabis and AOP is consistent across to European samples with expected differences in pattern of cannabis use (i.e. age at first use, frequency of use) Results: In the total sample, N = 935, comparing FEP who were cannabis users with never users, we found a significant difference in mean AOP (cannabis users: 28.30 (9.05) vs. non-users: 34.94 (12.5), t = -9.32, Po0.001). Moreover, 58% of cannabis users started at age ≤16 years old, with mean age of onset of Psychotic Disorder (25.47, sd = 7.03), compared with those who started later (M = 25.47, sd = 10.05) (t = -9.42, Po0.001). When the sample was split in NE and SE groups, we found that NE sample the mean AOP in cannabis users was 28.12 (±8.42) and 34.18 (±12.68) non-users (t = -4.65, Po0.001). In SE sample the mean AOP in cannabis users is 29.02 (±9.62) and in never users is 35.55 (±11.61) (t = -5.75, Po0.001). All predictors are statistically significant (in NE sample age first use β = .31, t = 5.16, P = .000, frequency β = -1.80, t = -2.93, Po0.001; in SE sample age first use β = 0.41, t = 6.67, P = .000, frequency β = -2.87, t = -4.66, Po0.001). In SE, the percentage of variance explained in a regression model is 31% (R2adj = .30) vs 16% (R2adj = .15) of NE. Discussion: Our results support the association between cannabis use and younger AOP in both samples, but were not observed significant difference across Europe. Linear regression model on predictors (age of first use, frequency of use) analyzed in the NE and the SE clinical samples confirmed relationship of causality with dependent variable (AOP), with a higher percentage of explained variance in sample of SE than NE.

Introduction The World Health Organization (WHO) considers stigma of mental illness as a crucial problem (WHO, 2001). Stigma contributes to the onset (Morgan et al., 2010) and the outcome of people affected by schizophrenia (Himan, 2015). Objectives To evaluate the perception of patients affected by psychotic disorders of being stigmatized by the community. Aims To compare the perception of stigma among subgroups of patients at different stage of their disorder. Methods Thirty-five patients affected by a first-episode of psychosis (FEP) and 96 patients affected by chronic psychosis were recruited. The Devaluation of Consumers Scale (DCS) and the Devaluation of Consumer Families Scale (DCFS) were administered to assess the perceived public stigma (Struening et al., 2001). The Positive And Negative Schizophrenic Symptoms Scale (PANSS) (Kay et al., 1987) and the Global Assessment of Functioning (GAF) (Goldman et al., 1992) were administered to assess psychotic symptoms and global level of functioning.Results Patients affected by chronic psychosis perceived higher devaluation against mental disorders than patients with a recent onset of psychosis (Mann–Whitney’s U = 910.500, P = 0.017). DCS and DCFS correlated with increased voluntary admissions (Rho = 0.355, P = 0.002; Rho = 0.257, P = 0.029) and DCS with increased compulsory admissions (Rho = 0.349, P = 0.003). Only among chronic patients, DCS factor 2 was related to global level of functioning (Rho = 0.217, P = 0.041). Conclusions Patients affected by chronic psychotic disorders perceived a more pessimistic attitude of the community towards their participation in social and community life and this is related to increased admissions and disability. Disclosure of interest The authors have not supplied their declaration of competing interest.

Objective This systematic review and meta‐analysis aimed to examine: the pooled prevalence of symptomatic behaviours and mental health deterioration amongst individuals with eating disorders (EDs) and obesity during the COVID‐19 confinement. Moreover, we examined changes in EDs and distress before and during the confinement, and the association between psychosocial factors and EDs symptoms. Method A systematic search was carried out in biomedical databases from January 2020 to January 2021. Both cross‐sectional and longitudinal studies that used quantitative measures of ED symptoms and psychological distress during and after the COVID‐19 confinement were included. Results A total of 26 studies met inclusion criteria (n = 3399, 85.7% female). The pooled prevalence of symptomatic deterioration in EDs was 65% (95% CI[48,81], k = 10). The pooled prevalence of increased weight in obesity was 52% (95% CI[25,78], k = 4). More than half of the participants experienced depression and anxiety. Moreover, at least 75% of the individuals with EDs reported shape and eating concerns, and increased thinking about exercising. However, the pooled analyses of longitudinal studies showed no significant differences from pre‐pandemic levels to the first lockdown phase in Body Mass Index and ED symptoms, whereas only few studies suggested increased distress, particularly among individuals with anorexia nervosa. Conclusions The majority of individuals with EDs and obesity reported symptomatic worsening during the lockdown. However, further longitudinal studies are needed to identify vulnerable groups, as well as the long‐term consequences of COVID‐19., Key points Sixty‐five percent of the individuals with Eating Disorders experienced symptom deterioration during the COVID‐19 confinementFifty‐two percent of the individuals with obesity reported weight increaseMore than half of the participants experienced depression and anxietyHowever, the few studies that examined changes in symptoms before and during the confinement showed inconsistent findingsHigh‐quality longitudinal studies are needed to identify vulnerable groups, as well as the long‐term impact of COVID‐19

Funder: FP7 Ideas: European Research Council; doi: http://dx.doi.org/10.13039/100011199; Grant(s): HEALTH-F2-2010-241909, Purpose: The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI) study contains an unparalleled wealth of comprehensive data that allows for testing hypotheses about (1) variations in incidence within and between countries, including by urbanicity and minority ethnic groups; and (2) the role of multiple environmental and genetic risk factors, and their interactions, in the development of psychotic disorders. Methods: Between 2010 and 2015, we identified 2774 incident cases of psychotic disorders during 12.9 million person-years at risk, across 17 sites in 6 countries (UK, The Netherlands, France, Spain, Italy, and Brazil). Of the 2774 incident cases, 1130 cases were assessed in detail and form the case sample for case–control analyses. Across all sites, 1497 controls were recruited and assessed. We collected data on an extensive range of exposures and outcomes, including demographic, clinical (e.g. premorbid adjustment), social (e.g. childhood and adult adversity, cannabis use, migration, discrimination), cognitive (e.g. IQ, facial affect processing, attributional biases), and biological (DNA via blood sample/cheek swab). We describe the methodology of the study and some descriptive results, including representativeness of the cohort. Conclusions: This resource constitutes the largest and most extensive incidence and case–control study of psychosis ever conducted.

Premorbid functioning and cognitive measures may reflect gradients of developmental impairment across diagnostic categories in psychosis. In this study, we sought to examine the associations of current cognition and premorbid adjustment with symptom dimensions in a large first episode psychosis (FEP) sample. We used data from the international EU-GEI study. Bifactor modelling of the Operational Criteria in Studies of Psychotic Illness (OPCRIT) ratings provided general and specific symptom dimension scores. Premorbid Adjustment Scale estimated premorbid social (PSF) and academic adjustment (PAF), and WAIS-brief version measured IQ. A MANCOVA model examined the relationship between symptom dimensions and PSF, PAF, and IQ, having age, sex, country, self-ascribed ethnicity and frequency of cannabis use as confounders. In 785 patients, better PSF was associated with fewer negative (B=-0.12, 95% C.I. -0.18, -0.06, p

The work was supported by Guarantors of Brain post-doctoral clinical fellowship to DQ; Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; Heisenberg professorship from the German Research Founda- tion (grant no. 389624707) to UR; the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0., Quattrone D., Reininghaus U., Richards A.L., Tripoli G., Ferraro L., Quattrone A., Marino P., Rodriguez V., Spinazzola E., Gayer-Anderson C., Jongsma H.E., Jones P.B., La Cascia C., La Barbera D., Tarricone I., Bonora E., Tosato S., Lasalvia A., Szöke A., Arango C., Bernardo M., Bobes J., Del Ben C.M., Menezes P.R., Llorca P.-M., Santos J.L., Sanjuán J., Arrojo M., Tortelli A., Velthorst E., Berendsen S., de Haan L., Rutten B.P.F., Lynskey M.T., Freeman T.P., Kirkbride J.B., Sham P.C., O’Donovan M.C., Cardno A.G., Vassos E., van Os J., Morgan C., Murray R.M., Lewis C.M., Di Forti M., Hubbard K., Beards S., Stilo S.A., Parellada M., Fraguas D., Castro M.R., Andreu-Bernabeu Á., López G., Matteis M., González E., Durán-Cutilla M., Díaz-Caneja C.M., Cuadrado P., Rodríguez Solano J.J., Carracedo A., Costas J., Sánchez E., Amoretti S., Lorente-Rovira E., Garcia-Portilla P., Jiménez-López E., Franke N., van Dam D., Termorshuizen F., van der Ven E., Messchaart E., Leboyer M., Schürhoff F., Jamain S., Baudin G., Ferchiou A., Pignon B., Richard J.-R., Charpeaud T., Tronche A.-M., Frijda F., Marrazzo G., Sideli L., Sartorio C., Seminerio F., Loureiro C.M., Shuhama R., Ruggeri M., Bonetto C., Cristofalo D., Berardi D., Seri M., D’Andrea G.

The association between childhood adversity (CA) and psychosis has been extensively investigated in recent years. An increasing body of research has also focused on the mediating or moderating role of biological and psychological mechanisms, as well as other risk factors that might account for the link between CA and psychosis. We conducted a systematic search of the PsychINFO, Embase, Ovid, and Web of Science databases for original articles investigating the role of genetic vulnerabilities, environmental factors, psychological and psychopathological mechanisms in the association between CA and psychosis up to August 2019. We included studies with individuals at different stages of the psychosis continuum, from subclinical psychotic experiences to diagnosed disorders. From the 28 944 records identified, a total of 121 studies were included in this review. Only 26% of the studies identified met the criteria for methodological robustness. Overall, the current evidence suggests that CA may be associated with psychosis largely independently of genetic vulnerabilities. More consistent and robust evidence supports interaction between early and recent adversities, as well as the mediating role of attachment and mood symptoms, which is suggestive of an affective pathway between CA and psychosis across the continuum from subclinical experiences to diagnosable disorder. This review highlighted numerous methodological issues with the existing literature, including selection bias, heterogeneity of measurement instruments utilised, and lack of control for potential confounders. Future research should address these limitations to more accurately estimate mediation and moderation effects on the CA-psychosis association to inform the development of preventive interventions.

Background: Accumulating evidence suggests that stigmatisation toward people with schizophrenia (PWS) is common among healthcare professionals and represents a major barrier to care. Aim: The study aimed at comparing the opinions about PWS among Italian medical students at different stages of education. Methods: Study participants were 234 medical students, attending either the first three-years pre-clinical or the following three-years clinical stage. Participants read an unlabelled case-vignette of schizophrenia and completed the Opinions on Mental Illness Questionnaire. Results: A greater proportion of students at the clinical stage identified schizophrenia in the clinical description, compared to their younger colleagues They were also more optimist about the efficacy of drug and psychological treatments and sceptical regarding the possibility of PWS to establish their own family. Conclusion: This study suggests that medical training may benefit from providing information about recovery from schizophrenia and contact with PWS in the community.

The GAP multidisciplinary study carried out in South London, recruited 410 first episode of psychosis patients and 370 controls; the aim was to elucidate the multiple genetic and environmental factors influencing the onset and outcome of psychosis. The study demonstrated the risk increasing effect of adversity in childhood (especially parental loss, abuse, and bullying) on onset of psychosis especially positive symptoms. Adverse life events more proximal to onset, being from an ethnic minority, and cannabis use also played important roles; indeed, one quarter of new cases of psychosis could be attributed to use of high potency cannabis. The “jumping to conclusions” bias appeared to mediate the effect of lower IQ on vulnerability to psychosis. We confirmed that environmental factors operate on the background of polygenic risk, and that genetic and environment act together to push individuals over the threshold for manifesting the clinical disorder. The study demonstrated how biological pathways involved in the stress response (HPA axis and immune system) provide important mechanisms linking social risk factors to the development of psychotic symptoms. Further evidence implicating an immune/inflammatory component to psychosis came from our finding of complement dysregulation in FEP. Patients also showed an upregulation of the antimicrobial alpha-defensins, as well as differences in expression patterns of genes involved in NF-κB signaling and Cytokine Production. Being of African origin not only increased risk of onset but also of a more difficult course of illness. The malign effect of childhood adversity predicted a poorer outcome as did continued use of high potency cannabis.

Background: Circuits is a computerized cognitive remediation program for individuals with schizophrenia. this study aimed to evaluate the feasibility of the italian version of circuits. MethODs: Feasibility was measured through ad-hoc questionnaires in a non-clinical sample (N.=30; target-score 70%; study 1); in patients with schizophrenia (N.=5; target-score 60%; study 2) and cr therapists (N.=3; target-score 60%; study 2). study 3 was a pilot study investigating: 1) enrolment, compliance, and retention rates; 2) satisfaction; 3) potential post-treatment and follow-up improvements in patients with schizophrenia (N.=20). these results were used to estimate sample size and feasibility for a future trial. resULts: all non-clinical participants rated high feasibility of circuits (83.3-100% scores). all patients (60-100% high-scores) and cr therapists (66-100% high-scores) evaluated circuits feasible. high rates of retention in treatment (74.5%) and satisfaction (85-100%) in patients were showed. Post-treatment assessment revealed an improvement in all cognitive measures. a sample size of 32 was calculated for each arm of the trial, at the desired power of 80%, to recruit for 18 months. cONcLUsiONs: results showed the feasibility of the italian version of circuits, they will inform a controlled future trial and implementation study of this therapy approach in the italian mental health system.

This study investigated the psychometric properties of the Dissociative Symptoms Scale (DSS) among Italian adults from outpatient and community samples. The DSS is a self-report measure of clinically relevant dissociation in adults. An Italian translation of the DSS was administered with measures of lifetime traumatic experiences, psychoform dissociation, and somatoform dissociation to 175 psychiatric outpatients and 423 individuals from the community. The DSS scores for outpatient and community adults were significantly different and showed good internal reliability, good convergent and construct validity, and a four-factor structure (depersonalization and derealization, gaps in awareness and memory, sensory misperceptions, and cognitive and behavioral reexperiencing) that was consistent with findings from previous research. Therefore, our results support previous research showing that the DSS can be used as a screening measure to assess clinically relevant dissociative experiences.

Objective: This review discusses the relationship between cannabis use and psychotic, bipolar, depressive, and anxiety disorders, as well as suicide. It summarizes epidemiological evidence from cross-sectional and long-term prospective studies and considers possible etiological mechanisms. Methods: Systematic reviews and methodologically robust studies in the field (from inception to February 2019) were identified using a comprehensive search of Medline, PsychINFO, and Embase and summarized using a narrative synthesis. Results: Consistent evidence, both from observational and experimental studies, has confirmed the important role of cannabis use in the initiation and persistence of psychotic disorders. The size of the effect is related to the extent of cannabis use, with greater risk for early cannabis use and use of high-potency varieties and synthetic cannabinoids. Accumulating evidence suggests that frequent cannabis use also increases the risk for mania as well as for suicide. However, the effect on depression is less clear and findings on anxiety are contradictory with only a few methodologically robust studies. Furthermore, the relationship with common mental disorders may involve reverse causality, as depression and anxiety are reported to lead to greater cannabis consumption in some studies. Pathogenetic mechanisms focus on the effect of tetrahydrocannabinol (THC, the main psychoactive ingredient of cannabis) interacting with genetic predisposition and perhaps other environmental risk factors. Cannabidiol (CBD), the other important ingredient of traditional cannabis, ameliorates the psychotogenic effects of THC but is absent from the high-potency varieties that are increasingly available. Conclusions: The evidence that heavy use of high-THC/low-CBD types of cannabis increases the risk of psychosis is sufficiently strong to merit public health education. Evidence of similar but smaller effects in mania and suicide is growing, but is not convincing for depression and anxiety. There is much current interest in the possibility that CBD may be therapeutically useful.

Nonostante i progressi della medicina e della chirurgia, i traumi da ustione a tutt’oggi rappresentano una causa significativa di menomazione e disabilita, comportano una significativa riduzione della qualita della vita e sono associati a diversi esiti psicopatologici, inclusi la depressione e il disturbo da stress post-traumatico. Questa revisione narrativa non sistematica della letteratura si propone di presentare le evidenze piu significative relative alla qualita della vita, ai sintomi psicopatologici, ai relativi fattori protettivi e di rischio, agli strumenti di valutazione e agli interventi psicologici rivolti ai pazienti ustionati. I risultati mostrano che la storia naturale delle lesioni da ustione e un processo complesso che coinvolge una varieta di fattori, tra cui l’insoddisfazione per l’immagine del corpo, le strategie di coping e il supporto sociale. Appare evidente che la valutazione del trauma da ustione debba tenere conto non solo degli effetti funzionali ed estetici del trauma, ma anche di quelli psicologici e sociali. Inoltre, e fondamentale che, in aggiunta ai trattamenti medici, chirurgici e riabilitativi, interventi psicologici siano resi disponibili a questi pazienti e ai loro familiari.

Aims: Cognitive impairment is a possible indicator of neurodevelopmental impairment, but not all psychotic patients are cognitively compromised. It has been suggested that heavy cannabis use may precipitate psychosis in those who show no such compromise. This study compares two samples of patients with first-episode psychosis and their respective non-psychotic controls, in London (UK) and Palermo (Italy), and examines whether different patterns of cannabis use are reflected in differences in IQ. Methods: The two studies used the same inclusion/exclusion criteria and instruments. The sample comprised 249 subjects from London (106 patients and 143 controls) and 247 subjects from Palermo (120 patients and 127 controls). ANCOVA was performed with IQ as the dependent variable and city and frequency of cannabis use as predictors. This was then repeated with the case group only, by adjusting for relevant confounders. Results: We found a greater amount of cannabis use in the London sample, compared to Palermo and patients from London had higher IQ than patients from Palermo, a difference that was more significant than that reflected between controls (Fjavax.xml.bind.JAXBElement@68a50fa4(1, 402) = 7.6, p = 0.006). Once corrected for symptomatology and treatment, patients from London who had never used cannabis were similar to patients from Palermo regarding IQ. Thus the higher IQ of patients from London was mainly due to the subgroup of cannabis-using patients (Fcannabis*city(2,145) = 4.6, p = 0.011). Conclusions: We can speculate that a greater amount of cannabis-use may have contributed by precipitating psychosis in patients with a higher IQ in London but less so in patients from Palermo.

Aim: Several studies have suggested that lifetime cannabis consumption and childhood abuse synergistically contribute to the risk for psychotic disorders. This study aimed to extend existing findings regarding an additive interaction between childhood abuse and lifetime cannabis use by investigating the moderating role of type and frequency of cannabis use. Methods: Up to 231 individuals presenting for the first time to mental health services with psychotic disorders and 214 unaffected population controls from South London, United Kingdom, were recruited as part of the Genetics and Psychosis study. Information about history of cannabis use was collected using the Cannabis Experiences Questionnaire. Childhood physical and sexual abuse was assessed using the Childhood Experience of Care and Abuse Questionnaire. Results: Neither lifetime cannabis use nor reported exposure to childhood abuse was associated with psychotic disorder when the other environmental variable was taken into account. Although the combination of the two risk factors raised the odds for psychosis by nearly three times (adjusted OR = 2.94, 95% CI: 1.44–6.02, P = 0.003), no evidence of interaction was found (adjusted OR = 1.46, 95% CI: −0.54 to 3.46, P = 0.152). Furthermore, the association of high-potency cannabis and daily consumption with psychosis was at least partially independent of the effect of childhood abuse. Conclusions: The heavy use of high-potency cannabis increases the risk of psychosis but, in addition, smoking of traditional resin (hash) and less than daily cannabis use may increase the risk for psychosis when combined with exposure to severe childhood abuse.

BAC KGROUND: Radiation therapy (RT ) has become one of the most widely-used and efficient treatments for cancer; nevertheless, people who undergo radiotherapy suffer the physical and psychological consequences of this stressful treatment, in addition to the psychosocial distress related to cancer. However, a Radiotherapy Unit is often a place where several patients crowd in from various hospitals with restricted timetables and, for logistic reasons, it is not easy to provide regular psychological sessions for each one. It is important to find a setting that allows us the involvement of the largest number of patients referred to the unit. In this study, we aimed to evaluate the feasibility and the effect of a brief intervention of cognitive-oriented diary on the quality of life, anxiety and depressive symptoms of patients undergoing radiotherapy (RT ), compared to a control group. METH ODS: The sample was constituted of 68 experimental subjects and 78 controls, treated with RT . Both groups were assessed with the Toronto Alexithymia Scale (TAS -20), the Hamilton Anxiety and Depression Scale (HA DS) and the EORTC -QLQ at the beginning and at the end of their RT . Experimental subjects were instructed to report emotions and thoughts before attending the RT sessions in a thought diary. RES ULTS : The experimental group showed a good adherence to the diary, a reduction in mean scores of anxiety (P

Psychological factors, specific lifestyles and environmental stressors may influence etiopathogenesis and evolution of chronic diseases. We investigate the association between Chronic Inflammatory Bowel Diseases (IBD) and psychological dimensions such as personality traits, defence mechanisms, and Alexithymia, i.e. deficits of emotional awareness with inability to give a name to emotional states. We analyzed a survey of 100 patients with IBD and a control group of 66 healthy individuals. The survey involved filling out clinical and anamnestic forms and administering five psychological tests. These were then analyzed by using a network representation of the system by considering it as a bipartite network in which elements of one set are the 166 individuals, while the elements of the other set are the outcome of the survey. We then run an unsupervised community detection algorithm providing a partition of the 166 participants into clusters. That allowed us to determine a statistically significant association between psychological factors and IBD. We find clusters of patients characterized by high neuroticism, alexithymia, impulsivity and severe physical conditions and being of female gender. We therefore hypothesize that in a population of alexithymic patients, females are inclined to develop psychosomatic diseases like IBD while males might eventually develop behavioral disorders.

IntroductionDiscrimination towards people with schizophrenia (PWS) by healthcare professionals is responsible of underdiagnosis and undertreatment of these patients. Negative attitudes toward PSW in health care professionals tend to be present since their university studies and are related to their knowledge and experience about the disease.Objectives and aimsTo assess opinion towards PSW in medical, nursing and psychology students and to investigate the relation with their knowledge of schizophrenia and its causes.MethodsThe study involved 133 medical, 200 nursing and 296 psychology undergraduate students. The opinion on mental illness questionnaire, the Devaluation Consumers Scale, and the Devaluation of Consumer Families Scale were administered to the sample. ANOVA and ANCOVA were used to test differences between groups and the relation between causal explanation of schizophrenia and discrimination towards PWS.ResultsPsychology students were more aware than the other student of public stigma towards PWS and their families (F 12.57, P < 0.001; F 32.69, P < 0.001) and expressed a more positive view on treatments’ effectiveness (F 30.74, P < 0.001). Psychology (OR 0.48, 95% CI 0.26–0.88) and nursing (OR 0.29, 95% CI 0.15–0.55) students were more likely to identify psychological and social risk factors as more frequent causes of schizophrenia (vs. biogenetics) and these, in turn, were related to a better opinion towards social equality of PWS.ConclusionsThese preliminary findings underline the relevance of biopsychosocial model of schizophrenia within stigma-reduction programs for health science students.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Nonostante la schizofrenia sia generalmente diagnosticata nella prima età adulta, circa il 4% dei casi provenienti da una coorte di nascita manifesterà il disturbo prima dei 18 anni. La Schizofrenia a Esordio Precoce (Early Onset Schizophrenia, EOS), a prescindere che si presenti nell’infanzia (Childhood Onset Schizophrenia, COS) o nell’adolescenza (Adolescent Onset Schizophrenia, AOS), è comunque associata a maggiori anomalie premorbose e decorso clinico ed esito psicosociale scadenti. Questi dati sottolineano l’importanza della diagnosi precoce e di trattamenti efficaci e sicuri per la schizofrenia in età infantile e adolescenziale. Il trattamento di bambini e adolescenti affetti da schizofrenia è particolarmente difficile in termini di ottimizzazione del benessere fisico ed emotivo e del funzionamento sociale, educativo e/o professionale, e anche nel tentativo di ridurre al minimo il carico che la malattia comporta per i pazienti e le loro famiglie. Ci sono lacune significative nella nostra comprensione di come un attuale intervento farmacologico possa interagire con lo sviluppo cognitivo e cerebrale e di come i cambiamenti evolutivi possono avere un impatto sulla risposta al trattamento a lungo termine. Allo stesso modo, i problemi di sicurezza e tollerabilità a lungo termine sono in gran parte irrisolti, nonostante le evidenze degli studi clinici in acuto su una maggiore sensibilità agli effetti collaterali nei pazienti EOS. Forse la sfida più grande è quella di progettare, implementare e valutare modelli di trattamento che vanno al di là del miglioramento sintomatico e si concentrano invece sull’integrazione sociale e sul recovery.

Il problema della violenza nelle persone affette da schizofrenia pone spinosi dilemmi clinici e sociali. Da una parte, il comportamento aggressivo nella schizofrenia può essere una pericolosa, anche se rara, complicanza della malattia. I medici sono tenuti ad anticipare, valutare, gestire e ridurre i rischi di violenza dei loro pazienti, con interventi e trattamenti adeguati. D’altra parte, pazienti psichiatrici capaci di decidere autonomamente, spesso riducono o sospendono il trattamento nel corso del tempo, il che è un loro diritto, e in ogni caso molte cause di violenza non possono essere trattate con i farmaci (Swanson et al., 2008a). Inoltre, concentrarsi semplicemente sul potenziale di violenza dei pazienti, può rappresentare una grossa limitazione nel passaggio verso la “normalizzazione” dei servizi di salute mentale nel territorio; ciò potrebbe addirittura rafforzare la deleteria percezione comune che gli individui affetti da patologie mentali siano pericolosi in generale, e quindi può contribuire indirettamente al rifiuto sociale ed allo stigma di cui le persone con disabilità psichiatriche continuano a fare esperienza nel territorio. I pazienti affetti da schizofrenia non sono, per la maggior parte, violenti. Tuttavia, la malattia conferisce un elevato rischio di violenza in confronto alla popolazione generale. Il rischio è ulteriormente aumentato da concomitanti disturbi da uso di sostanze e dalla non-aderenza al trattamento. La violenza nella schizofrenia è eziologicamente eterogenea. Le evidenze empiriche supportano almeno due sottotipi alternativi di violenza nella schizofrenia: uno in pazienti con storia di comportamenti antisociali nell’infanzia e un altro in pazienti senza questo fattore di rischio. I sintomi psicotici positivi sono legati alla violenza nel secondo sottotipo, ma non nel primo. Questa eterogeneità ha implicazioni in termini di gestione clinica. La violenza nei pazienti schizofrenici con storia di problemi della condotta nell’infanzia è probabilmente meno responsiva al trattamento farmacologico, e gli approcci non farmacologici aggiuntivi sono particolarmente appropriati nei pazienti in cui la violenza persistente non ha risposto ai soli farmaci. Esistono programmi cognitivo comportamentali promettenti. Una gestione efficace deve comprendere la capacità di avere a che fare con i disturbi da uso di sostanze in comorbilità e ogni sforzo deve essere concentrato nel mantenere l’aderenza al trattamento. Il trattamento farmacologico dell’agitazione acuta e dell’aggressività si basa su forme iniettabili di farmaci antipsicotici atipici (ziprasidone, olanzapina e aripiprazolo). Anche il lorazepam è ampiamente utilizzato, a volte in combinazione con l’aloperidolo. La clozapina è il farmaco di prima linea per il trattamento farmacologico a lungo termine del comportamento violento persistente nella schizofrenia. Altri antipsicotici hanno anche degli effetti anti-aggressivi, ma questi sono meno consistenti. Sono stati sperimentati gli anticonvulsivanti, il litio, i beta-bloccanti e gli SSRI, ma le prove per la loro efficacia anti-aggressiva sono limitate.

• The chapter focuses on premorbid Intellectual Quotient (IQ) in cannabis users, one of the most controversial topics in studies on the harmful effects of cannabis use on cognition. • Several studies have ascertained acute and residual effects of cannabis use in the memory domain, but only a minimal general cognitive effect after a long-term period of abstinence. • A number of longitudinal studies were able to obtain IQ measures before and after cannabis consumption, but they yielded discordant findings. • Authors, however, observed a relationship between higher premorbid IQ and recreational or discontinued use while a lower premorbid IQ resulted as a predictor for regular or heavy cannabis use. • Studies on cannabis use and cognitive impairment associated with schizophrenia paradoxically found better IQ among patients with cannabis use lifetime. • At the end of the chapter, authors proposed a conceptual table to summarize the complex relationship between premorbid IQ and cannabis use in determining different outcomes, by sustaining the hypothesis of a shared genetic vulnerability to psychosis and cannabis use,which is reflected on premorbid IQ and able to influence the contact with the substance. • In turn, cannabis may be a trigger for psychosis towards this continuum of a neurodevelopmental vulnerability.

Circa 1 persona su 20 affetta da schizofrenia morirà prematuramente per suicidio (Inskip, Harris, e Barraclough, 1998; Palmer, Pankratz, e Bostwick, 2005) e si stima che il 20% 50% realizzerà almeno un tentativo di suicidio nel corso della vita (Caldwell & Gottesman, 1990; Meltzer, 2002). La maggior parte dei suicidi portati a termine si verificano precocemente nel corso della malattia, con un rischio particolarmente alto nelle prime settimane dopo la dimissione dal primo ricovero (Appleby, Dennehy, Thomas, Faragher, e Lewis, 1999; Rossau & Mortensen, 1997), seguite dal primo anno e dai primi dieci anni dopo la diagnosi (Nordentoft et al, 2004; Palmer et al, 2005). Anche il periodo precedente alla prima presentazione è particolarmente critico, poiché fino al 10% degli individui commette almeno un tentativo di suicidio, prima di accedere per la prima volta alle cure psichiatriche (Clarke et al, 2006; Melle et al, 2006). La gestione del comportamento suicidario rappresenta una questione importante per la pratica clinica, soprattutto perché la gravità dei tentativi di suicidio (Harkavy- Friedman et al., 1999) realizzati dagli individui affetti da schizofrenia può avere conseguenze ugualmente devastanti per il paziente e la sua famiglia. Il comportamento suicidario nella schizofrenia può essere cronico o intermittente e richiede un monitoraggio continuo da parte di medici, pazienti e loro familiari e amici. È importante identificare i potenziali fattori di rischio per ogni singolo paziente e intervenire prima che si intensifichi il comportamento suicidario. È importante non farsi prendere dal panico e non rinunciare di fronte a pazienti con grave malattia mentale, dal momento che il miglioramento e il raggiungimento della qualità della vita desiderata può essere un impegno a lungo termine che offre gratificazioni significative. La comunicazione con i colleghi può aiutare il clinico nei momenti di preoccupazione per il rischio suicidario ed è altrettanto importante una comunicazione diretta con il paziente. I trattamenti farmacologici e sociali per la psicosi, la depressione e le altre condizioni di comorbidità sono in grado di prevenire o ridurre il comportamento suicidario. Il comportamento suicidario è un sintomo della schizofrenia che può essere affrontato con attenzione e cura. Migliorare la qualità della vita per le persone con schizofrenia dà la possibilità di ridurre il rischio di comportamenti suicidari.

Introduction There are strong enough evidences of the fact that risk of psychosis is augmented by cannabis use. In a recent analysis, the strongest predictor of case-control status was daily-skunk use, i.e. the ORs for skunk users increase with the frequency of use5. We know also that FEP who smoked cannabis in their lifetime are less neuropsychologically impaired i.e. they have better premorbid and current IQ6. In this study we wanted to test what augments the probability to be everyday users, taking into account premorbid social and academic adjustment and cognition as predictors, along with age at first cannabis-use and % of THC in cannabis used. Methods The sample was made of 834 First Episode Psychosis (FEP) cannabis-using and non-using patients from different European countries and 1.061 healthy controls, as part of the EUGEI-STUDY. A logistic regression was computed, using frequency of cannabis use among those who reported to have used cannabis in their lifetime, as an outcome variable in order to estimate the risk to be an everyday-user (heavy user) or a less-than-everyday user (recreational user), taking into account a list of predictors: sociodemographics, age at first cannabis-use, % of THC, premorbid social factor (PSF), premorbid academic factor (PAF), extracted from the Premorbid Adjustment Scale (PAS) and the four scales of WAIS-brief version. Results The risk to be an everyday-smoker was higher for cases, in interaction with age at first use, i.e. while the risk of controls diminishes when age at first use increases, this is not true for cases, whose risk stay higher even when age at first use increases (OR=1.2, p=0.001, CI 95% 1.09, 1.45). THC absolute concentration >10% augmented almost 2 folds the risk to be an everyday-smoker (OR=1.8, p=0.001, CI 95% 1.29, 2.60). A lower premorbid academic adjustment (OR=0.8, p=0.040, CI 95% 0.68, 0.99) and higher premorbid social adjustment before 16 years (OR=1.6, p=0.019, CI 95% 1.08, 2.60) increased the risk to be a heavy cannabis user, along with having a lower education level and being unemployed (all p